FREMONT, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. Cytek management is scheduled to participate in a hybrid presentation and fireside chat on Wednesday, March 4th at 8:10 a.m. Pacific Time / 11:10 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “In ...

Core Viewpoint - Cytek Biosciences, Inc. will report its financial results for Q4 and full year 2025 on February 26, 2026, with a conference call to discuss the results and outlook [1]. Company Overview - Cytek Biosciences is a leading company in cell analysis solutions, utilizing its patented Full Spectrum Profiling™ (FSP) technology to deliver high-resolution, high-content, and high-sensitivity cell analysis [2]. - The company's product offerings include core FSP instruments such as Cytek Aurora™, Northern Lights™, and Cytek Aurora™ Evo systems, as well as the Cytek Orion™ reagent cocktail preparation system and Enhanced Small Particle™ (ESP™) detection technology [2]. - Cytek is headquartered in Fremont, California, and has a global presence with offices and distribution channels [2]. Product Usage - Cytek's products are intended for research use only, with the exception of the Northern Lights-CLC system and certain reagents available for clinical use in China and the European Union [3]. Information Distribution - Cytek utilizes various channels, including its website, LinkedIn page, and X account, to distribute information about the company, products, and financial announcements, complying with Regulation FD [4].

Core Viewpoint - Cytek Biosciences, Inc. anticipates a total revenue of approximately $201 million for the full year 2025, with fourth-quarter revenue expected to be around $62 million, indicating growth compared to previous periods [2][3]. Financial Performance - The expected revenue for the fourth quarter of 2025 represents an 8% increase compared to the fourth quarter of 2024 and a 19% increase compared to the third quarter of 2025 [2]. - The fourth quarter revenue growth reflects a meaningful acceleration compared to earlier quarters in 2025, driven by strong growth in Services, Reagents, and instrument revenue in the Asia Pacific region, as well as improvements in the US and EMEA markets [3]. Company Presentation - Cytek will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 5:15 PM Pacific Time, with live and archived webcasts available on the company's website [4]. Company Overview - Cytek Biosciences is a leading cell analysis solutions company that utilizes its patented Full Spectrum Profiling™ (FSP) technology to deliver high-resolution and high-sensitivity cell analysis tools [5]. - The company's product offerings include various flow cytometers, imaging products, reagents, and software, aimed at providing a comprehensive suite of solutions for customers [5].

Core Insights - Cytek Biosciences, Inc. has been recognized as one of America's Growth Leaders of 2026 by TIME in partnership with Statista, highlighting its exceptional growth, financial stability, and stock performance over the past five years [1][14]. Company Overview - Cytek Biosciences specializes in high-parameter cell analysis solutions, utilizing its patented Full Spectrum Profiling™ (FSP) technology to deliver innovative tools for laboratories [7]. - The company is headquartered in Fremont, California, and has a global presence with offices and distribution channels [7]. Financial Performance - The inclusion in TIME's list signifies Cytek's strong financial foundation and sustained business expansion, reflecting its ability to deliver long-term value [2][5]. - Cytek's FSP systems are referenced in over 3,200 peer-reviewed publications, indicating their significant impact on global research [4]. Innovation and Technology - Cytek's mission is to make high-parameter cell analysis more accessible and cost-effective, addressing urgent challenges in health and science, such as cancer research and vaccine development [3]. - The company's FSP technology sets a new standard in flow cytometry, enhancing the precision and sensitivity of cell analysis [3][7]. Market Position - Being named to the Growth Leaders list places Cytek among an elite group of companies demonstrating resilience and a forward-looking approach in a dynamic market [5].

Core Insights - Cytek Biosciences, Inc. will report its financial results for Q3 2025 on November 5, 2025, after market close, followed by a conference call to discuss the results and outlook [1] Company Overview - Cytek Biosciences is a leading company in cell analysis solutions, utilizing its patented Full Spectrum Profiling™ (FSP) technology to deliver high-resolution and high-sensitivity cell analysis tools [2] - The company's product offerings include FSP instruments such as Cytek Aurora™, Northern Lights™, and Cytek Orion™, along with various reagents and software, providing a comprehensive suite of solutions for customers [2] - Cytek is headquartered in Fremont, California, with a global presence through offices and distribution channels [2] Product Usage - Cytek's products are intended for research use only, with specific exceptions for clinical use in China and the European Union for certain systems and reagents [3] Information Distribution - The company utilizes multiple channels, including its website, LinkedIn, and X account, to disseminate material information and comply with disclosure obligations under Regulation FD [4]

Core Insights - Cytek Biosciences has relocated its European headquarters to a new facility in Amsterdam's Life Sciences District, reflecting its commitment to the EMEA region and enhancing service for customers [1][4] - The new site has increased the company's footprint by over 40% and includes a dedicated customer service and training center, providing hands-on training for researchers [2] - The success of Cytek's reagent business is a major driver for this expansion, with the company transitioning warehouse operations in-house to improve operational efficiency and quality control [3] Company Overview - Cytek Biosciences is a leading cell analysis solutions company that utilizes its patented Full Spectrum Profiling™ (FSP) technology to deliver high-resolution and high-sensitivity cell analysis tools [5] - The company's product offerings include various systems and technologies designed to enhance multiplexing capabilities and provide comprehensive solutions for researchers [5] - Cytek's products are primarily for research use, with certain systems available for clinical use in specific regions [6] Strategic Importance - Europe is identified as a key region for Cytek's global growth, and the new Amsterdam facility is expected to enhance the company's capabilities in delivering solutions and services across the EMEA region [4][15] - The expansion aims to support scientific understanding and accelerate data-driven decision-making, fostering innovation within the industry [4]

Core Insights - Cytek Biosciences, a leader in spectral flow cytometry, is set to showcase its advanced solutions at two major industry events, emphasizing the growing demand for deeper cellular insights in cancer research and diagnostics [1][4] Company Overview - Cytek Biosciences specializes in high-resolution, high-content, and high-sensitivity cell analysis tools, utilizing its patented Full Spectrum Profiling™ (FSP) technology [8] - The company's FSP systems have been referenced in over 2,800 peer-reviewed publications, indicating widespread acceptance and application in the research community [2] Technology and Innovation - Cytek's Full Spectrum Profiling™ technology allows for the profiling of more than 40 markers in a single tube, significantly enhancing efficiency and reducing analysis time [7] - The integration of spectral flow cytometry with machine learning is being explored to simplify data analysis and reduce technician workload, as demonstrated in workshops at upcoming conferences [4][6] Industry Events - The European Society for Clinical Cell Analysis (ESCCA) 2025 Conference will take place from September 17 to September 20, 2025, in Montpellier, France, focusing on clinical applications in various fields [3] - The ICCS Annual Meeting & Course will be held from September 28 to September 30, 2025, in Philadelphia, bringing together professionals to advance knowledge in clinical cytometry [5] Leadership and Expertise - Dr. Wenbin Jiang, CEO of Cytek, highlighted the advantages of spectral flow cytometry in enabling laboratories to achieve more with less, thereby allowing scientists to focus on high-skill tasks [7] - Workshops led by experts like Dr. Joseph C. Lownik and Dr. Paul K. Wallace will present innovative approaches to using spectral flow cytometry for accurate diagnosis of leukemia and lymphoma [4][6]

Core Viewpoint - Cytek Biosciences, Inc. will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, indicating its active engagement in the healthcare investment community [1]. Company Overview - Cytek Biosciences is a leading cell analysis solutions company that specializes in high-resolution, high-content, and high-sensitivity cell analysis through its patented Full Spectrum Profiling™ (FSP) technology [3]. - The company offers a comprehensive suite of products including the Cytek Aurora™, Northern Lights™, and Cytek Orion™ systems, as well as flow cytometers and imaging products under the Amnis and Guava brands [3]. - Cytek is headquartered in Fremont, California, with a global presence through offices and distribution channels [3]. Upcoming Events - Cytek management is scheduled for a fireside chat on June 11 at 11:40 a.m. Pacific Time, which will be accessible via a live and archived webcast on the company's website [2].

Core Insights - Cytek Biosciences is committed to advancing cell analysis through its patented Full Spectrum Profiling™ (FSP) technology, which will be showcased at key industry events such as CYTO 2025 and IMMUNOLOGY2025 [1][2][5] Company Overview - Cytek Biosciences, Inc. (Nasdaq: CTKB) is a leading company in cell analysis solutions, focusing on high-resolution, high-content, and high-sensitivity tools [6][7] - The company’s FSP technology enhances multiplexing capabilities with precision and sensitivity, positioning it as a pioneer in spectral flow cytometry [6][2] Industry Events - At IMMUNOLOGY2025, Cytek will present its complete cell analysis solutions, including instruments, reagents, and software, aimed at advancing research and discovery [3][4] - The company will also host a workshop on in-depth characterization of mouse immune responses during the event [4] - CYTO 2025 will feature Cytek as a Platinum sponsor, where it will showcase technology designed to accelerate scientific discovery [4][5] Strategic Goals - Cytek aims to make flow cytometry technology more accessible and scalable, unlocking new opportunities in high-growth areas such as immunology, oncology, and cell therapy [2][5] - The company emphasizes its commitment to delivering innovative and flexible solutions to empower researchers and accelerate breakthroughs in scientific advancement [5]